ArticleCancer cell2018
Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 1 pooled it
7.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 1 synthesis or guideline pooled it, 212 citations in OpenAlex.
- Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.Acta neuropathologica · 2019Pooled it
- Scalable clinical proteomics from DNA/RNA extraction flowthroughs enables integrated proteogenomic profiling from a single cancer biopsy.Clinical proteomics · 2026Article
- CReP-mediated control of eIF2α phosphorylation is a critical node in MYC-driven medulloblastoma.Nature communications · 2026Article
- The BAIAP2 pathway regulates proliferation and migration in medulloblastoma.The Journal of biological chemistry · 2026Article
- APT MRI Signature for Risk Stratification of Pediatric Medulloblastoma.Chemical & biomedical imaging · 2026Article
- Immune Cell Therapy Promises More Effective Cure for Medulloblastoma.Journal of personalized medicine · 2026Review
- Comprehensive proteogenomic characterization reveals clinically relevant molecular subtypes associated with medulloblastoma progression.Experimental & molecular medicine · 2026Article
- Preservation and clonal behavior of extrachromosomal DNA in patient-derived xenograft models of childhood cancers.Genome medicine · 2026Article
- Global impact of germline structural variation on the cancer proteome.Nature communications · 2026Article
- A tissue-specific atlas of protein-protein associations enables prioritization of candidate disease genes.Nature biotechnology · 2026Article
- Article
- Distinct cMET inhibitors uncover pharmacological heterogeneity in SHH medulloblastoma cell lines.Discover oncology · 2026Article
- Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma.Cancer cell · 2026Article
- Identification of Raptor and GLI1 as USP37 substrates highlight its context-specific function in medulloblastoma cells.Oncogene · 2026Article
- Medulloblastoma stem cell programs: Molecular roadmaps of disease progression.Developmental cell · 2026Review
- Integration of high-throughput proteomic data and complementary omics layers with PriOmics.Genome research · 2026Article
- Erythrocyte-microglia crosstalk contributing to sex differences in pediatric brain tumorigenesis.Research square · 2025Article
- In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients.Scientific reports · 2025Article
- Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer.Cancer discovery · 2025Article
- The role of DNA methylation in directing treatment in medulloblastoma.Epigenomics · 2025Review
72 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
31 authors at 7 institutions in 3 countries.
Tenley C ArcherDepartment of Neurology, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA; Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Tobias EhrenbergerDepartment of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.
Filip MundtEli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Maxwell P GoldDepartment of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.
Karsten KrugEli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Clarence K MahDepartment of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
Elizabeth L MahoneyDepartment of Neurology, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Colin J DanielDepartment of Molecular and Medical Genetics, Oregon Health and Science University (OHSU), Portland, OR, USA.
Alexander LeNailDepartment of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.
Divya RamamoorthyDepartment of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.
Philipp MertinsEli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
D R ManiEli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Hailei ZhangEli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Michael A GilletteHarvard Medical School, Boston, MA, USA; Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA; Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital (MGH), Boston, MA, USA.
Karl ClauserEli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Michael NobleEli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Lauren C TangEli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Jessica Pierre-FrançoisDepartment of Neurology, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Jacob SilterraEli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
James JensenDepartment of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
Pablo TamayoDepartment of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA; Moores Cancer Center, University of California San Diego (UCSD), La Jolla, CA, USA.
Andrey KorshunovCCU Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neuropathology, Heidelberg University, Heidelberg, Germany.
Stefan M PfisterHopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany; Department of Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Marcel KoolHopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Paul A NorthcottDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany; Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, TN, USA.
Rosalie C SearsDepartment of Molecular and Medical Genetics, Oregon Health and Science University (OHSU), Portland, OR, USA.
Jonathan O LiptonDepartment of Neurology, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA.
Steven A CarrEli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: scarr@broadinstitute.org.
Jill P MesirovDepartment of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA; Moores Cancer Center, University of California San Diego (UCSD), La Jolla, CA, USA. Electronic address: jmesirov@ucsd.edu.
Scott L PomeroyDepartment of Neurology, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: scott.pomeroy@childrens.harvard.edu.
Ernest FraenkelEli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA. Electronic address: fraenkel-admin@mit.edu.
Broad Institute · USMassachusetts Institute of Technology · USUniversity of California San Diego · USBoston Children's Hospital · USGerman Cancer Research Center · DEOregon Health & Science University · USSt. Jude Children's Research Hospital · US
Funding
TRAINING IN SLEEP, CIRCADIAN &RESPIRATORY NEUROBIOLOGYT32HL007901 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Charles A Czeisler · 1998 to 2026
$18.5MUnderstanding the Impact of Microscale and Nanoscale Heterogeneity and ResistanceU54CA209988 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI GRAY, JOE W. · 2017 to 2021
$10.3MGENOMIC ANALYSIS OF MEDULLOBLASTOMASR01CA109467 · NCI · CHILDREN'S HOSPITAL BOSTON · PI MESIROV, JILL P., POMEROY, SCOTT LOREN · 2004 to 2015
$7.3MSupporting Integrative Genomic Analysis Users with GenePatternR01GM074024 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P. · 2005 to 2019
$6.6MCenter of Excellence for High Throughput Proteogenomic CharacterizationU24CA210986 · NCI · BROAD INSTITUTE, INC. · PI CARR, STEVEN A, GILLETTE, MICHAEL A · 2016 to 2020
$6.4MMouse Neurodevelopmental Behavior CoreU54HD090255 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI SAHIN, MUSTAFA · 2016 to 2020
$5.2MKnowledge-based Gene Expression Analysis for Biomedical and Cancer ResearchR01CA121941 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P. · 2006 to 2016
$5.1MA Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic StatesU01CA217885 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI COHEN, EZRA, KAUFMAN, DAN S. · 2017 to 2021
$5.1MGraduate Training in Computational and Systems BiologyT32GM087237 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B · 2009 to 2023
$4.6MIntegrated high throughput proteogenomic data analysis center for CPTACU24CA210979 · NCI · BROAD INSTITUTE, INC. · PI BIRGER, CHET, GETZ, GAD A · 2016 to 2020
$4.4MHydroxylation regulation of c-MycR01CA186241 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mu-Shui Dai, ROSALIE C SEARS · 2015 to 2026
$4.2MThe Integrative Genomics Viewer (IGV): visualization supporting cancer researchU24CA210004 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P., ROBINSON, JAMES THOMAS · 2016 to 2020
$3.8MNCI NIH HHS R01 CA109467NCI NIH HHS R01 CA121941NCI NIH HHS R01 CA154480NCI NIH HHS R01 CA186241NCI NIH HHS R01 CA196228NCI NIH HHS U01 CA184898NCI NIH HHS U01 CA217885NCI NIH HHS U24 CA194107NCI NIH HHS U24 CA210004NCI NIH HHS U24 CA210979NCI NIH HHS U24 CA210986NCI NIH HHS U54 CA209988NHLBI NIH HHS T32 HL007901NICHD NIH HHS U54 HD090255NIGMS NIH HHS R01 GM074024NIGMS NIH HHS T32 GM087237
Abstract
There is a pressing need to identify therapeutic targets in tumors with low mutation rates such as the malignant pediatric brain tumor medulloblastoma. To address this challenge, we quantitatively profiled global proteomes and phospho-proteomes of 45 medulloblastoma samples. Integrated analyses revealed that tumors with similar RNA expression vary extensively at the post-transcriptional and post-translational levels. We identified distinct pathways associated with two subsets of SHH tumors, and found post-translational modifications of MYC that are associated with poor outcomes in group 3 tumors. We found kinases associated with subtypes and showed that inhibiting PRKDC sensitizes MYC-driven cells to radiation. Our study shows that proteomics enables a more comprehensive, functional readout, providing a foundation for future therapeutic strategies.
Indexed as
Protein Processing, Post-TranslationalAdolescentAdultBiomarkers, TumorBrain NeoplasmsCell Line, TumorChildChild, PreschoolDNA-Activated Protein KinaseDNA MethylationFemaleGene Expression ProfilingHedgehog ProteinsHumansInfantMaleBiomarkers, TumorDNA-Activated Protein KinaseHedgehog ProteinsMYC protein, humanNuclear ProteinsPRKDC protein, humanProteomeProto-Oncogene Proteins c-mycSHH protein, humanmass spectrometrymedulloblastomamulti-omicsMYCnetwork integrationNU-7441phospho-proteomicsproteo-genomicsradio sensitizationSHH
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.